BST-DERMON Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

Phase 3TerminatedNCT00434538

BioSyntech Canada Inc.40 enrolled

Overview

This trial is designed to investigate the therapeutic benefits of using BST-DermOn for the wound repair of diabetic neuropathic foot ulcers. The objective of this study is to evaluate the safety and efficacy of BST-DermOn in providing a clinically significant advantage over the standard of care in the repair of diabetic foot ulcers.

This trial is designed to investigate the therapeutic benefits of using BST-DermOn for the wound repair of diabetic neuropathic foot ulcers. BST-DermOn is a sterile, non-toxic, nonpyrogenic wound dressing composed of an aqueous mixture of Chitosan, hydrochloric acid (HCl) and disodium beta-glycerol phosphate (β-GP) designed to address current wound healing needs. Chitosan has well documented wound healing properties as well as inherent haemostatic and bacteriostatic capabilities. BST-DermOn is used in conjunction with a defined standard of care and is applied over a prepared and debrided ulcer and covered with a semi-occlusive secondary dressing. This prospective, multi-center, randomized, controlled study will enrol 130 type 1 or type 2 diabetic subjects presenting with a Grade 1 or Grade 2 (Wagner classification) diabetic foot ulcer of 1-10cm² on the mid or forefoot. Subjects who meet the eligibility criteria will be assigned to one of two groups: 1. a control group that will receive the standard of care or 2. a treatment group that will receive BST-DermOn. Treatments in both groups will be applied three (3) times a week for up to twenty consecutive weeks or until the study ulcer is closed. All subjects will be followed for safety and efficacy during treatment visits through a final evaluation visit. There will be a post treatment follow-up visit at 4 weeks post-closure for subjects with complete re-epithelialization. The objective of this study is to evaluate the safety and efficacy of BST-DermOn in providing a clinically significant advantage over the standard of care in the repair of diabetic foot ulcers.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetic Foot Ulcer

Interventions

BST-DermOnDEVICE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Between eighteen (18) and eighty (80) years of age * Type 1 or Type 2 diabetes mellitus * Diabetes is under adequate control * Diabetic foot ulcer located on the mid or forefoot * Diabetic foot ulcer has been present for at least four (4) weeks and no more than two (2) years prior to screening * Diabetic foot ulcer is ≥ 1.0cm² and ≤10cm² in size * Diabetic foot ulcer is grade 1 or 2 according to the Wagner Grading system. Exclusion Criteria: * Ulcer is over an active Charcot deformity of the mid-foot ("Rocker-Bottom Foot") or over the talus, distal calcaneous, navicular, or cuboid bones or a deformity that interfere with off-loading in the opinion of the investigator * Ulcer due to a non-diabetic aetiology * Ulcer has tunnels or sinus tracts that cannot be completely debrided. * Clinical evidence of infection * Osteomyelitis * Subject has vasculitis, severe rheumatoid arthritis, other collagen or vascular diseases or other medical conditions, outside of diabetes, known to impair wound healing.

Locations (20)

Foothills Medical Center Col Belcher Hospital

Calgary, Alberta, Canada

Outcomes

Primary Outcomes

Percentage of subjects with closed ulcers at week 12

Secondary Outcomes

Reduction in size of the diabetic foot ulcer at week 20.

Safety by analysis of AEs.

Reduction of incidence of clinical signs of infection.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.